http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
P. Sangeetha,Harika Madireddy,B. Varshini,R. B. Yokesh 한국강구조학회 2024 International Journal of Steel Structures Vol.24 No.2
This paper aims to study the experimental and analytical behaviour of cold-formed steel (CFS) T-joint members with or without external ring stiff eners under combined axial compression and bending. The parameters varied in the study include the type of T-joints (with and without ring stiff eners), spacing of the stiff eners (100 mm and 200 mm from the central axis of the T-Joint), and thickness of the ring stiff eners (4 mm and 6 mm). The load–defl ection and load-strain behaviour were studied by measuring the overall defl ection of the T-joints and strain using dial gauges and strain indicators, respectively. The load-carrying capacity of the T-joints with external ring stiff eners was compared, and the results of a numerical investigation showed good agreement. An extensive parametric study was carried out for diff erent geometric parameters of the ring stiff ener, chord, and brace member using the FE model to obtain the ultimate strength of the stiff ened T-joints, and strength was also compared and obtained using the published equation. From the results of this investigation, it was found that the T-joints with external ring stiff eners can resist more strength and deformation when compared to the T-joints without external ring stiff eners.
The Codon 399 Arg/Gln XRCC1 Polymorphism is Associated with Lung Cancer in Indians
Natukula, Kirmani,Jamil, Kaiser,Pingali, Usha Rani,Attili, Venkata Satya Suresh,Madireddy, Umamaheshwar Rao Naidu Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.9
Background: The XRCC1 (X-ray repair cross complimenting group-I) gene in BER (base excision repair) pathway is essential for DNA repair process. Polymorphisms in this gene are associated with variations in the repair efficiency which might predispose individuals to development of various cancers. Two variants of XRCC1gene (at codon 399), Gln/Gln and Arg/Gln, have been shown to be related to lowered DNA repair capacity and increased genomic instability in multiple studies. Hence our investigation focused on genotyping these variants to correlate with other multiple risk factors in lung cancer (NSCLC) patients since we hypothesized that these variants of the XRCC1 gene might influence disease susceptibility. Materials and Methods: We examined the frequency of the polymorphism in one hundred cases and an almost equal number of controls after recording their demographics with a structured questionnaire. Genomic DNA from blood samples was extracted for PCR studies, followed by RFLP to determine the variants. The significance of the data was statistically analyzed. Results: The three genotypes in cases and controls were Arg/Arg (40% and 54.45%); Gln/Gln (19% and 9.90%), and Arg/Gln (41.0% and 35.64%) respectively. Among these 3 genotypes, we found Gln/Gln and Arg/Gln to show association with lung cancer. Correlating these genotypes with several parameters, we also found that these two variants were associated with risk in males (p<0.05) and with smoking habits (p<0.05). In females Arg/Gln genotype showed association with stage of the disease (p=0.04). This is the first report in South Indian scenario where Arg399Gln genotypes were found to be associated with stage of the disease in females. Conclusions: It is concluded that XRCC1 genotypes Gln/Gln and Arg/Gln may influence cancer susceptibility in patients with smoking habits and these functional SNPs in XRCC1 gene may act as attractive candidate biomarkers in lung cancer for diagnosis and prognosis.
Natukula, Kirmani,Jamil, Kaiser,Pingali, Usha Rani,Attili, Venkata Satya Suresh,Madireddy, Umamaheshwar Rao Naidu Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.8
Background: The wide spectrum of clinical features in advanced stages of non-small cell lung cancer (NSCLC) probably contributes to disparities in outcomes because of different prognostic variables significant for stage IIIB/IV patients. Hence the aim of this study was to check for favorable response of patients to various chemotherapeutic combinations with respect to patient survival in stage IIIB and stage IV NSCLC disease. We selected those patients for our study who were receiving treatment with paclitaxel, gemcitabine or etoposide in combination with platinum based drugs. Materials and Methods: Seventy-two patients who visited the hospital from June 2009 to November 2012 with confirmed diagnosis of lung cancer were included, and data were collected for follow up and classified according to treatment received with respect to patients' regimen and response, and overall survival. This study analyzed tumor variables that were associated with clinical outcome in advanced NSCLC patients who were undergoing first-line chemotherapy for stage IIIB/IV NSCLC. Results: Comparative data on various parameters like age, gender, stage, histology, site of disease, metastatic site and chemo-regimens was analyzed; these parameters predicted variable significant improvement for overall survival ($p{\geq}0.05$). One and two year survival rates were 20.8% and 15.3%. Conclusions: In this study we found slight improvement in survival rates in NSCLC and clinical outcomes with one combination (carboplatin+paclitaxel). Overall there were only marginal differences in survival rates for other chemo-regimens evaluated in this study.
Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies
Madireddi, Shravan,Eun, So-Young,Lee, Seung-Woo,Nemč,ovič,ová,, Ivana,Mehta, Amit Kumar,Zajonc, Dirk M.,Nishi, Nozomu,Niki, Toshiro,Hirashima, Mitsuomi,Croft, Michael The Rockefeller University Press 2014 The Journal of experimental medicine Vol.211 No.7
<P>Biologics to TNF family receptors are prime candidates for therapy of immune disease. Whereas recent studies have highlighted a requirement for Fcγ receptors in enabling the activity of CD40, TRAILR, and GITR when engaged by antibodies, other TNFR molecules may be controlled by additional mechanisms. Antibodies to 4-1BB (CD137) are currently in clinical trials and can both augment immunity in cancer and promote regulatory T cells that inhibit autoimmune disease. We found that the action of agonist anti–4-1BB in suppressing autoimmune and allergic inflammation was completely dependent on Galectin-9 (Gal-9). Gal-9 directly bound to 4-1BB, in a site distinct from the binding site of antibodies and the natural ligand of 4-1BB, and Gal-9 facilitated 4-1BB aggregation, signaling, and functional activity in T cells, dendritic cells, and natural killer cells. Conservation of the Gal-9 interaction in humans has important implications for effective clinical targeting of 4-1BB and possibly other TNFR superfamily molecules.</P>